Twist Bioscience Stock News

Twist Bioscience (NASDAQ:TWST) released its quarterly earnings results on Monday. The company reported ($0.84) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.80) by ($0.04), MarketWatch Earnings reports. The company had revenue of $37.95 million during the quarter, compared to analysts expectations of $36.26 million. Twist Bioscience had a negative return []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 19,983 shares of Twist Bioscience stock in a transaction on Monday, November 22nd. The stock was sold at an average price of $101.83, for a total transaction of $2,034,868.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. []

Twist Bioscience Corp

On Monday, Twist Bioscience Corp (NASDAQ:TWST) shares declined by more than 8% after announcing its fiscal fourth-quarter results. The company reported its most recent quarterly results before markets opened, missing the consensus analyst expectation on earnings per share. However, TWST marginally beat the Street revenue forecast after a double-digit Y/Y sales growth. Twist posted FQ4 [] The post Twist Bioscience stock prediction after plunging 8% on earnings miss appeared first on Invezz.

Twist Bioscience Corporation (NASDAQ: TWST ) reported a 17% Y/Y increase in its Q4 revenues to $37.95 million , beating the Wall Street estimate of $37.02 million, driven by strength in SynBio, NGS, biopharma businesses. The Company shipped products to approximately 2,900 customers in fiscal 2021, versus about 2,200 in fiscal 2020. The Company posted a wider net loss of Full story available on Benzinga.com

On Monday, Twist Bioscience Corp (NASDAQ:TWST) shares declined by more than 8% after announcing its fiscal fourth-quarter results. The company reported its most recent quarterly results before markets

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its sili

Twist Bioscience Corporation (NASDAQ: TWST) reported a 17% Y/Y increase in its Q4 revenues to $37.95 million, beating the Wall Street estimate of $37.02 million, driven by strength in SynBio, NGS, b

Twist Bioscience Co. (NASDAQ:TWST) Director Jan Johannessen sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 17th. The stock was sold at an average price of $115.17, for a total value of $575,850.00. The transaction was disclosed in a document filed with the SEC, which is available through this []

Twist Bioscience (TWST) delivered earnings and revenue surprises of -5% and 3.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience Corporation (NASDAQ:TWST)s traded shares stood at 0.72 million during the last session. At the close of trading, the stocks price was $110.62, to imply a decrease of -1.36% or -$1.53 in intraday trading. The TWST shares 52-week high remains $214.07, putting it -93.52% down since that peak but still an impressive 23.86% since Twist Bioscience Corporation (NASDAQ: TWST): Can A Stock Be -21.71% Lower Year-To-Date And Still Be A Loser? Read More »